» Articles » PMID: 16353905

Pharmacodynamic Parameter Estimation: Population Size Versus Number of Samples

Overview
Journal AAPS J
Specialty Pharmacology
Date 2005 Dec 16
PMID 16353905
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study was to evaluate the effects of population size, number of samples per individual, and level of interindividual variability (IIV) on the accuracy and precision of pharmacodynamic (PD) parameter estimates. Response data were simulated from concentration input data for an inhibitory sigmoid drug efficacy (E(max)) model using Nonlinear Mixed Effect Modeling, version 5 (NONMEM). Seven designs were investigated using different concentration sampling windows ranging from 0 to 3 EC(50) (EC(50) is the drug concentration at 50% of the E(max)) units. The response data were used to estimate the PD and variability parameters in NONMEM. The accuracy and precision of parameter estimates after 100 replications were assessed using the mean and SD of percent prediction error, respectively. Four samples per individual were sufficient to provide accurate and precise estimate of almost all of the PD and variability parameters, with 100 individuals and IIV of 30%. Reduction of sample size resulted in imprecise estimates of the variability parameters; however, the PD parameter estimates were still precise. At 45% IIV, designs with 5 samples per individual behaved better than those designs with 4 samples per individual. For a moderately variable drug with a high Hill coefficient, sampling from the 0.1 to 1, 1 to 2, 2 to 2.5, and 2.5 to 3 EC(50) window is sufficient to estimate the parameters reliably in a PD study.

Citing Articles

Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling.

Kim Y, Lee J, Jang H, Zang D, Lee D Antibiotics (Basel). 2022; 11(6).

PMID: 35740150 PMC: 9220236. DOI: 10.3390/antibiotics11060743.


Population Pharmacodynamic Modeling Using the Sigmoid E Model: Influence of Inter-individual Variability on the Steepness of the Concentration-Effect Relationship. a Simulation Study.

Proost J, Eleveld D, Struys M AAPS J. 2020; 23(1):10.

PMID: 33367961 PMC: 7759489. DOI: 10.1208/s12248-020-00549-7.


Impact of Sampling Period on Population Pharmacokinetic Analysis of Antibiotics: Why do You Take Blood Samples Following the Fourth Dose?.

Kim S, Kim D, Zang D, Lee D Pharmaceuticals (Basel). 2020; 13(9).

PMID: 32947890 PMC: 7558941. DOI: 10.3390/ph13090249.


Parameter estimation for sigmoid E models in exposure-response relationship.

Choe S, Lee D Transl Clin Pharmacol. 2020; 25(2):74-84.

PMID: 32133323 PMC: 7042008. DOI: 10.12793/tcp.2017.25.2.74.


Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations.

Papathanasiou T, Strathe A, Hooker A, Lund T, Overgaard R AAPS J. 2018; 20(3):64.

PMID: 29687351 DOI: 10.1208/s12248-018-0226-5.


References
1.
Sheiner L, Beal S . Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981; 9(4):503-12. DOI: 10.1007/BF01060893. View

2.
Kelman A, Whiting B . Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm. 1990; 18(4):347-60. DOI: 10.1007/BF01062273. View

3.
White D, Walawander C, Tung Y, Grasela T . An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis. J Pharmacokinet Biopharm. 1991; 19(1):87-112. DOI: 10.1007/BF01062194. View

4.
Sun H, Ette E, Ludden T . On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data. J Pharmacokinet Biopharm. 1996; 24(6):637-50. DOI: 10.1007/BF02353484. View

5.
Braat M, Jonkers R, Bel E, van Boxtel C . Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers. Clin Pharmacokinet. 1992; 22(3):231-7. DOI: 10.2165/00003088-199222030-00005. View